Dennis Grewal, DO
Cardiovascular Disease · Santa Ana, CANPI 1538556592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,544 of the $5,583 with a category attached, or 81.4%. 21 manufacturers reported payments, led by Shockwave Medical, Inc at 35.6% of the total. 2025 is the largest year on record at $1,891, more than ten times the $93 reported in 2019.
Across 70 payments — averaging $79.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$2K
- Abbott$1K
- Penumbra, Inc.$575
- Biotronik Inc.$543
- Bayer$196
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
- plus $891 from 15 others
Across 5 payments — averaging $5381.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$27K
What the payments were for
- Travel & lodging$1,03819%
- Food & beverage$4,54481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 13 | $1,988 |
| Abbott | 13 | $1,216 |
| Penumbra, Inc. | 4 | $575 |
| Biotronik Inc. | 5 | $543 |
| Bayer | 4 | $196 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $174 |
| Medtronic(2 entities) | 4 | $167 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $135 |
| Philips North America LLC | 1 | $103 |
| Kestra Medical Technology Services, Inc. | 2 | $93 |
| Novartis | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Boehringer Ingelheim | 3 | $63 |
| Boston Scientific | 1 | $43 |
| Recor Medical Inc | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Cleerly, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Bsn Medical Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,871
- MitraClip$873
- Indigo System$450
- BioMonitor$296
- Acticor 7 VR-T DX$132
- Edora 8 DR-T$132
- Rivacor 7 DR-T$132
- Kerendia$125
- Selectra$124
- Micra$124
- US Und$103
How this compares
$5,583 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $102,134 |
| EntrestoSacubitril/Valsartan | 68 | $79,044 |
| FarxigaDapagliflozin Propanediol | 48 | $45,170 |
| JardianceEmpagliflozin | 21 | $21,259 |
| XareltoRivaroxaban | 19 | $18,519 |
| Repatha SureclickEvolocumab | 11 | $10,557 |
| BrilintaTicagrelor | 13 | $8,654 |
| Atorvastatin Calcium | 249 | $2,648 |
| Metoprolol Succinate | 184 | $2,259 |
| Ezetimibe | 59 | $2,050 |
| Bisoprolol Fumarate | 33 | $1,151 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $1,021 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 23 | $958 |
| Rosuvastatin Calcium | 65 | $887 |
| Losartan Potassium | 105 | $873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $69 | $79,04468 claims |
| Boehringer IngelheimJardiance | $63 | $21,25921 claims |
| Johnson & JohnsonXarelto | $20 | $18,51919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Santa Ana
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.